CN111471637A - 2' -fucosyllactose high-yield strain and preparation method and application thereof - Google Patents
2' -fucosyllactose high-yield strain and preparation method and application thereof Download PDFInfo
- Publication number
- CN111471637A CN111471637A CN202010379802.3A CN202010379802A CN111471637A CN 111471637 A CN111471637 A CN 111471637A CN 202010379802 A CN202010379802 A CN 202010379802A CN 111471637 A CN111471637 A CN 111471637A
- Authority
- CN
- China
- Prior art keywords
- coli
- plasmid
- duet
- enzyme digestion
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940062827 2'-fucosyllactose Drugs 0.000 title claims abstract description 18
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 title claims abstract description 18
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 title claims abstract description 18
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 241000588724 Escherichia coli Species 0.000 claims abstract description 22
- 229930006000 Sucrose Natural products 0.000 claims abstract description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 17
- 239000005720 sucrose Substances 0.000 claims abstract description 16
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 102100024515 GDP-L-fucose synthase Human genes 0.000 claims abstract description 5
- 108030006298 GDP-L-fucose synthases Proteins 0.000 claims abstract description 5
- 108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 claims abstract description 5
- 102000002312 GDPmannose 4,6-dehydratase Human genes 0.000 claims abstract description 5
- GBXZONVFWYCRPT-KVTDHHQDSA-N [(2s,3s,4r,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] dihydrogen phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C=O)OP(O)(O)=O GBXZONVFWYCRPT-KVTDHHQDSA-N 0.000 claims abstract description 4
- 239000013612 plasmid Substances 0.000 claims description 93
- 238000001976 enzyme digestion Methods 0.000 claims description 71
- 239000012634 fragment Substances 0.000 claims description 43
- 238000000855 fermentation Methods 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 230000004151 fermentation Effects 0.000 claims description 32
- 239000003292 glue Substances 0.000 claims description 24
- 238000011144 upstream manufacturing Methods 0.000 claims description 24
- PFLZGJUQPYLVMP-UHFFFAOYSA-O 3-(3-methylbut-2-enyl)-7h-purin-3-ium-6-amine Chemical compound CC(C)=CC[N+]1=CN=C(N)C2=C1N=CN2 PFLZGJUQPYLVMP-UHFFFAOYSA-O 0.000 claims description 22
- 102000012410 DNA Ligases Human genes 0.000 claims description 21
- 108010061982 DNA Ligases Proteins 0.000 claims description 21
- 238000012408 PCR amplification Methods 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 21
- 238000012795 verification Methods 0.000 claims description 20
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 18
- 241001640034 Heteropterys Species 0.000 claims description 15
- 230000029087 digestion Effects 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 229960005322 streptomycin Drugs 0.000 claims description 9
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 8
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 229960000723 ampicillin Drugs 0.000 claims description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 6
- 229960005091 chloramphenicol Drugs 0.000 claims description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 101150066555 lacZ gene Proteins 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 108010038016 Mannose-1-phosphate guanylyltransferase Proteins 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 101710098620 Alpha-1,2-fucosyltransferase Proteins 0.000 claims description 3
- 241000143940 Colias Species 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000003209 gene knockout Methods 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 101150030355 scrB gene Proteins 0.000 claims description 3
- 101150086685 scrY gene Proteins 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims 4
- 230000003698 anagen phase Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 241000588722 Escherichia Species 0.000 abstract description 5
- 101100075927 Aspergillus aculeatus mndA gene Proteins 0.000 abstract description 4
- 101100022282 Escherichia coli O157:H7 manC2 gene Proteins 0.000 abstract description 4
- 101150088678 manB gene Proteins 0.000 abstract description 4
- 101150032120 manC gene Proteins 0.000 abstract description 4
- 241000579120 Coliiformes Species 0.000 abstract description 2
- 101001010029 Lactobacillus helveticus Putative phosphotransferase enzyme IIA component Proteins 0.000 abstract description 2
- 108090000992 Transferases Proteins 0.000 abstract description 2
- 102000004357 Transferases Human genes 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 56
- 238000004977 Hueckel calculation Methods 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- 150000002482 oligosaccharides Chemical class 0.000 description 11
- 235000020256 human milk Nutrition 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 description 2
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 description 2
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 2
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 description 2
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 2
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229910052564 epsomite Inorganic materials 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 2
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 2
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101000885514 Arabidopsis thaliana Putative fucosyltransferase-like protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910004835 Na2B4O7 Inorganic materials 0.000 description 1
- -1 ROA organic acid Chemical class 0.000 description 1
- QUOQJNYANJQSDA-MHQSSNGYSA-N Sialyllacto-N-tetraose a Chemical compound O1C([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](OC2[C@H]([C@H](OC3[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@@H]1O QUOQJNYANJQSDA-MHQSSNGYSA-N 0.000 description 1
- SFMRPVLZMVJKGZ-JRZQLMJNSA-N Sialyllacto-N-tetraose b Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O1 SFMRPVLZMVJKGZ-JRZQLMJNSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052927 chalcanthite Inorganic materials 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 229930193965 lacto-N-fucopentaose Natural products 0.000 description 1
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QNSWVQWPVUZACH-XCVMNONQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5r,6s)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3r,4r,5r)-1,2,5-trihydroxy-6-oxo-4-[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyhexan-3-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6- Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@H](O[C@H]3[C@H]([C@H](O)[C@H](O)[C@H](C)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 QNSWVQWPVUZACH-XCVMNONQSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- SXMGGNXBTZBGLU-UHFFFAOYSA-N sialyllacto-n-tetraose c Chemical compound OCC1OC(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC(C(C(O)C1O)O)OC1COC1(C(O)=O)CC(O)C(NC(C)=O)C(C(O)C(O)CO)O1 SXMGGNXBTZBGLU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07013—Mannose-1-phosphate guanylyltransferase (2.7.7.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y504/00—Intramolecular transferases (5.4)
- C12Y504/02—Phosphotransferases (phosphomutases) (5.4.2)
- C12Y504/02008—Phosphomannomutase (5.4.2.8)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a 2' -fucosyllactose high-yield strain, a preparation method and application thereof, wherein the preservation number of the strain is CGMCC No. 19557. The invention uses Escherichia coliE.coliB L21 (DE3) is a production host, a synthetic route of 2'-F L is constructed by over-expressing phosphomannose mutase (manB), mannose-1-phosphoguanyltransferase (manC), GDP-mannose-4, 6-dehydratase (gmd), GDP-L-fucose synthase (flc) and α -1, 2-fucose transferase (futC), on the basis, the substrate supply is improved by over-expressing sucrose transporter and lactose transporter, the production capacity of 2' -F L is further improved, high-efficiency expression of 2'-F L in escherichia coli is realized, and a 2' -F L high-yield strain is obtained.
Description
Technical Field
The invention relates to a 2' -fucosyllactose high-yield strain and a preparation method and application thereof.
Background
Human milk is a complex mixture of carbohydrates, fats, proteins, vitamins, minerals and trace elements. The main component is carbohydrates, which can be further divided into lactose and more complex oligosaccharides (human milk oligosaccharides, HMOs). Lactose, however, can be used by the human body as an energy source, and complex oligosaccharides cannot be metabolized by infants. Complex oligosaccharides consist of more than 200 different oligosaccharides, the content of which amounts to up to 20% of the total carbohydrate content. The presence and concentration of these complex oligosaccharides is unique to humans and has not been found in emulsions in other mammals.
About 200 structurally diverse HMOs have been identified to date, and many beneficial properties thereof have been reported. HMO is not digestible by breast-fed infants, but is available as Bifidobacterium in the gut: (Bifidobacteria) Lactobacillus (I) and (II)Lactobacillus) And Bacteroides genus (Bacteroides) And the carbon source and the energy source of the beneficial bacteria enable the bacteria to dominate the intestinal tract and overcome pathogens in competition, and can prevent the intestinal epithelial infection. Furthermore, HMOs can also bind directly to pathogenic bacteria, protozoa, and viruses, blocking pathogen-host interactions by mimicking glycan cell surface receptors, thereby protecting breastfed children from infectious diseases.
Among the numerous human milk oligosaccharides, the most important is 2' -fucosyllactose (2' -fucosylactose, 2' -F L.) other important HMOs present in human milk are 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, and lacto-N-fucopentaose, in addition to these neutral oligosaccharides, acidic HMOs such as 3' -sialyllactose, 6' -sialyllactose, and sialyllacto-N-tetraose a, b, and c, or sialyllacto-N-fucopentaose II, etc. these structures are closely related to the epitope of the epithelial cell surface glycoconjugate (L ewis tissue blood group antigen), and structural homology of HMOs to epithelial epitopes suggests that they have protective properties against bacterial pathogens.
Due to their beneficial properties, it is advantageous to include HMOs as a component in infant formulas and other food products, which makes the mass production of HMOs (up to the ton grade) the gist of current oligosaccharide production. Due to the limited supply and the difficulty of obtaining the purity of individual human milk oligosaccharides, chemical routes to some of these complex molecules were developed. However, chemical and biocatalytic processes that have proven to be commercially unsustainable, and furthermore, the chemical synthetic routes of especially human milk oligosaccharides involve several toxic chemicals, which carries the risk of contaminating the final product.
Today, for several HMOs such as 2'-F L, 3' -fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-difucohexose II, 3 '-sialyllactose and 6' -sialyllactose, related microbial fermentation processes have been developed, which mainly use genetically engineered bacterial strains such as recombinant escherichia coli (escherichia coli) ((r) ("b))Escherichia coli,E.coli)。
However, even the most efficient processes currently available based on bacterial fermentation, HMO titers in the fermentation broth of greater than 20 g/L cannot or are hardly achieved the industrial grade processes must usually exceed titers of 50 g/L, although 100 g/L is more desirable.
Disclosure of Invention
The object of the present invention is to provide a 2' -fucosyllactose high-producing strain that makes it possible to achieve high titer, and a method for preparing and use thereof.
The technical solution of the invention is as follows:
2' -fucosyllactose high-yield strain(s) ((Escherichia coli) The method is characterized in that: the preservation number is CGMCC No. 19557.
The 2' -fucosyllactose high-producing strain(s) ((Escherichia coli) The preparation method is characterized in that: comprises the following steps:
(1) construction ofE.coliBL21(DE3)-1:
To be provided withEscherichia coliMG1655, using genome as a template, designing a primer: an upstream primer:manB-F: CCGGAATTCATGATAAATATGGTCGTGTTGAGGA, downstream primer:manB-R: CGCGGATCCTTACAAAAGAGTAACTTTATGCAAA, respectively; PCR amplification of phosphomannose mutase (manB) expression genemanBA sequence; the PCR product was reacted with pCDF-Duet plasmidEcoRI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product ismanBConnecting the gene fragment and the pCDF-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:manC-F: CCCAAGCTTATGAGCTCACCTCTTATTCCGGTTA, downstream primer:manC-R: AAATATGCGGCCGCTCAATCTTCAAATCGAAGGATATCA, respectively; PCR amplification of mannose-1-phosphate guanylyltransferase (manC) expression GenemanCA sequence; the PCR product was mixed with pCDF-Duet-manBPlasmid carrying outHindIII/NotI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productmanCGene fragment and pCDF-Duet-manBCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB-manC;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:gmd-F: GGGAATTCCATATGTCAAAAGTCGCTCTCATCACCG, and the downstream primer:gmd-R: CGGGGTACCATGTCAAAAGTCGCTCTCATCACCG are provided. PCR amplification of GDP-mannose-4, 6-dehydratase (gmd) expression GenegmdA sequence; the PCR product was mixed with pCDF-Duet-manB-manCPlasmid carrying outNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productgmdGene fragment and pCDF-Duet-manB-manCCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB-manC-gmd;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:flc-F: CCGGAATTCATGAGTAAACAACGAGTTTTTATTG, downstream primer:flcCGCGGATCCTTACCCCCGAAAGCGGTCTTGATTC, PCR amplification of GDP-L-fucose synthase (flc) expression GeneflcA sequence; the PCR product was reacted with pACYC-Duet plasmidEcoRI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product isflcConnecting the gene fragment and the pACYC-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a chloramphenicol resistant plate, plasmid extraction and enzyme digestion or PCR verification are carried out, and the successfully constructed plasmid pACYC-Duet-flc;
Based onHelicobacter pyloriα -1, 2-fucosyltransferase (futC) sequence provided in genome, synthesized by Shanghai Productivity based on codon preference of Escherichia colifutCSequence, design of upstream primer:futC-F: GGGAATTCCATATGGCTTTTAAGGTGGTGCAAATTT, downstream primer:futCCGCGGATCCTTAAGCGTTATACTTTTGGGATTTC, PCR amplification α -1, 2-fucosyltransferase (futC) gene, and the PCR product and pACYC-Duet plasmidNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productfutCGene fragment and pACYC-Duet-flcCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a chloramphenicol resistant plate, plasmid extraction and enzyme digestion or PCR verification are carried out, and the successfully constructed plasmid pACYC-Duet-flc-futC(ii) a The above plasmid pCDF-Duet-manB-manC-gmd、pACYC-Duet-flc-futCConstruction of transformed E.coli B L21 (DE3)E.coliBL21(DE3)-1;
(2) Constructing to obtain recombinant strainE.coliBL21(DE3)-3:
Using Bacillus subtilis (B), (B)Bacillus subtilis) 168 genome is used as a template, and an upstream primer is designed:scrB-F: CATGCCATGGATGACAGCACATGACCAGGAGCTTC, downstream primer:scrB-R: CGCGGATCCCTACATAAGTGTCCAAATTCCGACA, respectively; PCR amplification of scrB expression gene of one of sucrose transportersscrBA sequence; the PCR product was reacted with pET-Duet plasmidNcoI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product isscrBConnecting the gene fragment and pET-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 competes, transformants are screened and cultured by an ampicillin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain the successfully constructed plasmid pET-Duet-scrB;
To be provided withE. coliThe K-12 genome is used as a template, and an upstream primer is designed:scrY-F: GGGAATTCCATATGATGTATAAAAAAACAACTTTGGCAG, downstream primer:scrY-R: CGGGGTACCTTAAAACCAGGTTTCCATTTGGACA are provided. PCR amplification of scrY expression gene of one of sucrose transportersscrYA sequence;
the PCR product was reacted with pET-Duet plasmidNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productscrYGene fragment and pET-Duet-scrBCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 competes, transformants are screened and cultured by an ampicillin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain the successfully constructed plasmid pET-Duet-scrB-scrY. The plasmid pET-Duet-scrB - scrYTransformation of the plasmid intoE. coliB L21 (DE3) -1, recombinant strains were obtainedE.coliBL21(DE3)-2;
To be provided withE. coliB L21 (DE3) genome as template, designing sgRNA and homology arm primer for gene knockout, PCR amplifying lacZ gene upstream and downstream homology arms, obtaining pure knockout gene segment after recovery of glue, and graftingE. coliB L21 (DE3)/pKD46 was cultured at 30 ℃ and OD600When 0.1 was reached, L-arabinose was added at a final concentration of 0.2% to induce expression of pKD 46-lambda-red system when OD was reached600When the content of the compound (B) is 0.3 to 0.4, the feeling of preparation is obtainedCompetent, addition of a knock-out gene fragment to competence, after electrotransformation, knock-outlacZGene to obtain recombinant bacteriumE. coliBL21(DE3)-2/△lacZ;
The recombinant strain is prepared byE.coliBL21(DE3)-2/△lacZRespectively designing for starting strainslacY-F: GGGAATTCCATATGATGTACTATTTAAAAAACACAAACT, downstream primer:lacY-R: CGCGGATCCTTAAGCGACTTCATTCACCTGACGA, amplificationE. colilacY-expressing Gene in K-12lacYRespectively fusing the gene with a strong promoter PssrA in escherichia coli through fusion PCR to construct a high-efficiency expression reading coding frame of lacY; then, the expression cassette is integrated into the recombinant strain by using a homologous integration system in Escherichia coli, and the recombinant strain is constructedE.coliB L21 (DE3) -3, 2' -fucosyllactose high producing strainEscherichia coli。
The application of the 2'-fucosyllactose high-yield strain in improving the yield of 2' -F L is characterized in that a recombinant strain is usedE.coliB L21 (DE3) -3 was inoculated into seed medium and cultured overnight at 37 ℃ and OD was determined at 30 ℃6000.8 hours, 0.5 mM IPTG was added, and the fermentation time was 96 hours, under which conditions the concentrations of sucrose and fructose in the fermentation medium were 30 g/L and 20 g/L, respectively.
Recombinant bacteriaE.coliA single colony of B L21 (DE3) -3 strain is cultured in a seed solution with a liquid loading of 100 m L at 30 ℃ and 180r/min by a rotary shaking table to OD600The method is characterized by taking the seed solution with the concentration of 10.0 percent approximately, inoculating 60 m L of the seed solution into a fermentation culture medium with the working volume of 3L with the inoculation amount of 2.0 percent, fermenting at the fermentation temperature of 33 ℃ in a fermentation tank, stirring at the rotating speed of 600 r/min, the ventilation amount of 1vvm and the pH value of 6.8 (adding ammonia water for automatic control), adding IPTG with the concentration of 50 mg/m L in 1-2 m L in the logarithmic phase, adding sucrose after the logarithmic phase is ended until the concentration is 22 g/L, adding the initial 6h at the flow rate of 9 m L/h, then adding 115 h at the flow rate of 9 m L/h, and adding 100 g/L in the fermentation liquid 2' -F L after the fermentation is ended.
The invention uses Escherichia coliE.coliB L21 (DE3) as production host by overexpressing mannosylmutase phosphate (manB), mannose-1-phosphate guanylyltransferase ((R))manC), GDP-mannose-4, 6-dehydratase (gmd), GDP-L-fucose synthase (flc) and α -1, 2-fucose transferase (futC), a synthetic route of 2'-F L is constructed, on the basis, the supply of substrates is improved by over-expressing sucrose transporter and lactose transporter, the production capacity of 2' -F L is further improved, the 2'-F L is efficiently expressed in escherichia coli, and a 2' -F L high-yield strain is obtained.
The present invention will be further described with reference to the following examples.
The 2' -fucosyllactose high-yield strain has a preservation number of CGMCC No. 19557. And (3) classification and naming: escherichia coli, latin literature name:Escherichia coliand the preservation unit: china general microbiological culture Collection center, address: xilu l No. 3, Beijing, Chaoyang, Beijing, on the north of the Chaoyang district, with a preservation date of 2020, 4 months and 7 days.
Detailed Description
Culture medium:
the seed culture medium comprises sucrose 5.0 g/L, nitrogen source and trace elements 1.0 g/L yeast extract, and 2.0 g/L NH4Cl,10.0 g/L Na2HPO4·7H2O,3.0 g/L KH2PO4,0.5 g/L NaCl,0.25 g/L MgSO4·7H2O,15.0 mg/L CaCl2·2H2O and 10 mg/L vitamin B1.
The fermentation medium comprises sucrose 22.0 g/L and sucrose 13.5 g/L KH2PO4,4.0 g/L (NH4)2H2PO41.7 g/L citric acid, 1.4 g/L MgSO4·7H2O, 10 mg/L solution of trace elements (10 g/L ferric citrate, 2.25 g/L ZnSO)4·7H2O,10 g/L CuSO4·5H2O,0.35 g/L MnSO4·H2O,0.23 g/L Na2B4O7·10H2O,0.11g/L (NH4)6Mo7O24,2.0 g/L CaCl2·2H2O )
Analytical method
In the following, concentration detection was performed using a spectrophotometer (Biomate 5, Thermo, n.y., USA), intracellular FucT2 enzyme protein was detected using 12% SDS-PAGE, after 3 h addition of 0.1 mM IPTG, the cells were collected and adjusted to a concentration of 7.2 g/L, resuspended and sonicated using 50 mM phosphate buffer (pH 7.0), followed by centrifugation at 15000 g for 20min to pellet the supernatant, and then analyzed by gel electrophoresis.
The 2-F L yields were analyzed using high performance liquid chromatography HP L C (Agilent Technologies 1200 Series) equipped with a Rezex ROA organic acid column H + (Phenomenex, Torrance, Calif. USA) and an RI detector (Agilent, Palo Alto, Calif., USA). The column was tested using 0.01M sulfuric acid at a flow rate of 0.6M L/min, at a column temperature of 50 ℃.
To confirm the purity of 2' -F L, the fermentation broth was collected and assayed by L C/MS, where L C (Agilent technologies 1100 Series) was equipped with an Agilent Zorbax Eclipse ZDB-C8 (4.6 x150 mM, 5 micron) column and an Agilent L C/MSD capture XCT Plus detector at a column flow rate of 0.4 ml/min, with the elution procedure being 95% (v/v) eluent A (15 mM ammonium acetate) and 5% eluent B (acetonitrile) for 1 min, increasing the B concentration from 5% to 95% over 6 min, followed by 95% B wash for 10 min, where MS was assayed in the range of 70-600 (m/z).
2' -fucosyllactose high-yield strain(s) ((Escherichia coli) The preparation method comprises the following specific steps:
(1) construction ofE.coliBL21(DE3)-1:
To be provided withEscherichia coliMG1655 genome is used as template, designing primer: an upstream primer:manB-F: CCGGAATTCATGATAAATATGGTCGTGTTGAGGA, downstream primer:manB-R: CGCGGATCCTTACAAAAGAGTAACTTTATGCAAA, respectively; PCR amplification of phosphomannose mutase (manB) expression genemanBA sequence; the PCR product was reacted with pCDF-Duet plasmidEcoRI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product ismanBConnecting the gene fragment and the pCDF-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened by streptomycin resistant plates and cultured, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain the structureSuccessfully constructed plasmid pCDF-Duet-manB;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:manC-F: CCCAAGCTTATGAGCTCACCTCTTATTCCGGTTA, downstream primer:manC-R: AAATATGCGGCCGCTCAATCTTCAAATCGAAGGATATCA, respectively; PCR amplification of mannose-1-phosphate guanylyltransferase (manC) expression GenemanCA sequence; the PCR product was mixed with pCDF-Duet-manBPlasmid carrying outHindIII/NotI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productmanCGene fragment and pCDF-Duet-manBCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB-manC;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:gmd-F: GGGAATTCCATATGTCAAAAGTCGCTCTCATCACCG, and the downstream primer:gmd-R: CGGGGTACCATGTCAAAAGTCGCTCTCATCACCG are provided. PCR amplification of GDP-mannose-4, 6-dehydratase (gmd) expression GenegmdA sequence; the PCR product was mixed with pCDF-Duet-manB-manCPlasmid carrying outNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productgmdGene fragment and pCDF-Duet-manB-manCCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB-manC-gmd;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:flc-F: CCGGAATTCATGAGTAAACAACGAGTTTTTATTG, downstream primer:flcCGCGGATCCTTACCCCCGAAAGCGGTCTTGATTC, PCR amplification of GDP-L-fucose synthase (flc) expression GeneflcA sequence; the PCR product was reacted with pACYC-Duet plasmidEcoRI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product isflcGene fragment and pACYC-DueCarrying out overnight connection on the t plasmid enzyme digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a chloramphenicol resistant plate, plasmid extraction and enzyme digestion or PCR verification are carried out, and the successfully constructed plasmid pACYC-Duet-flc;
Based onHelicobacter pyloriα -1, 2-fucosyltransferase (futC) sequence provided in genome, synthesized by Shanghai Productivity based on codon preference of Escherichia colifutCSequence, design of upstream primer:futC-F: GGGAATTCCATATGGCTTTTAAGGTGGTGCAAATTT, downstream primer:futCCGCGGATCCTTAAGCGTTATACTTTTGGGATTTC, PCR amplification α -1, 2-fucosyltransferase (futC) gene, and the PCR product and pACYC-Duet plasmidNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productfutCGene fragment and pACYC-Duet-flcCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a chloramphenicol resistant plate, plasmid extraction and enzyme digestion or PCR verification are carried out, and the successfully constructed plasmid pACYC-Duet-flc-futC(ii) a The above plasmid pCDF-Duet-manB-manC-gmd、pACYC-Duet-flc-futCConstruction of transformed E.coli B L21 (DE3)E.coliBL21(DE3)-1;
(2) Constructing to obtain recombinant strainE.coliBL21(DE3)-3:
Using Bacillus subtilis (B), (B)Bacillus subtilis) 168 genome is used as a template, and an upstream primer is designed:scrB-F: CATGCCATGGATGACAGCACATGACCAGGAGCTTC, downstream primer:scrB-R: CGCGGATCCCTACATAAGTGTCCAAATTCCGACA, respectively; PCR amplification of scrB expression gene of one of sucrose transportersscrBA sequence; the PCR product was reacted with pET-Duet plasmidNcoI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product isscrBConnecting the gene fragment and pET-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 was competent, transformants were selected on ampicillin-resistant plates and cultured, and plasmid extraction andthe plasmid pET-Duet-scrB;
To be provided withE. coliThe K-12 genome is used as a template, and an upstream primer is designed:scrY-F: GGGAATTCCATATGATGTATAAAAAAACAACTTTGGCAG, downstream primer:scrY-R: CGGGGTACCTTAAAACCAGGTTTCCATTTGGACA are provided. PCR amplification of scrY expression gene of one of sucrose transportersscrYA sequence;
the PCR product was reacted with pET-Duet plasmidNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productscrYGene fragment and pET-Duet-scrBCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 competes, transformants are screened and cultured by an ampicillin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain the successfully constructed plasmid pET-Duet-scrB-scrY. The plasmid pET-Duet-scrB - scrYTransformation of the plasmid intoE. coliB L21 (DE3) -1, recombinant strains were obtainedE.coliBL21(DE3)-2;
To be provided withE. coliB L21 (DE3) genome as template, designing sgRNA and homology arm primer for gene knockout, PCR amplifying lacZ gene upstream and downstream homology arms, obtaining pure knockout gene segment after recovery of glue, and graftingE. coliB L21 (DE3)/pKD46 was cultured at 30 ℃ and OD600When 0.1 was reached, L-arabinose was added at a final concentration of 0.2% to induce expression of pKD 46-lambda-red system when OD was reached600When the gene reaches 0.3-0.4, preparing competence, adding a knockout gene segment into the competence, and after electrotransformation, knocking out the knockout gene segmentlacZGene to obtain recombinant bacteriumE. coliBL21(DE3)-2/△lacZ;
The recombinant strain is prepared byE.coliBL21(DE3)-2/△lacZRespectively designing for starting strainslacY-F: GGGAATTCCATATGATGTACTATTTAAAAAACACAAACT, downstream primer:lacY-R: CGCGGATCCTTAAGCGACTTCATTCACCTGACGA, amplificationE. colilacY-expressing Gene in K-12lacYRespectively fusing the gene with a strong promoter PssrA in escherichia coli through fusion PCR to construct a high-efficiency expression reading coding frame of lacY; subsequently, homologous integration in E.coli was usedA system for integrating the expression frame into the recombinant strain to construct a recombinant strainE.coliB L21 (DE3) -3, 2' -fucosyllactose high producing strainEscherichia coli。
The application of the 2'-fucosyllactose high-yield strain in improving the yield of 2' -F L is to use a recombinant strainE.coliB L21 (DE3) -3 is inoculated into seed culture medium, cultured overnight at 37 deg.C, transferred to fermentation medium at 1%, 5% and 10% inoculum concentration respectively, and treated with OD600Increasing to 0.6-0.8, adding 0.1, 0.5 and 1mM IPTG, cooling on ice for 20min, inducing fermentation at 20, 25, 30 and 37 deg.C for 120 hr, sampling at 12 hr intervals, measuring the yield of 2-F L, and determining OD at 30 deg.C6000.8 hour, adding 0.5 mM IPTG, and taking fermentation time of 96 hours as an optimal fermentation condition, wherein under the condition, the concentrations of sucrose and fructose in a fermentation medium are respectively 30 g/L and 20 g/L, the thallus concentration can reach 18 g/L, and the yield of 2' -F L can reach 35 g/L.
Based on the fermentation conditions, the fermentation conditions of Escherichia coli 2-F L are optimized in a 3L fermentation tank, and the recombinant bacteria are subjected to fermentationE.coliA single colony of B L21 (DE3) -3 strain is cultured in a seed solution with a liquid loading of 100 m L at 30 ℃ and 180r/min by a rotary shaking table to OD600The method is characterized by taking the seed solution with the concentration of 10.0 percent approximately, inoculating 60 m L of the seed solution into a fermentation culture medium with the working volume of 3L with the inoculation amount of 2.0 percent, fermenting at the fermentation temperature of 33 ℃ in a fermentation tank, stirring at the rotating speed of 600 r/min, the ventilation amount of 1vvm and the pH value of 6.8 (adding ammonia water for automatic control), adding IPTG with the concentration of 50 mg/m L in 1-2 m L in the logarithmic phase, adding sucrose after the logarithmic phase is ended until the concentration is 22 g/L, adding the initial 6h at the flow rate of 9 m L/h, then adding 115 h at the flow rate of 9 m L/h, and adding 100 g/L in the fermentation liquid 2' -F L after the fermentation is ended.
The related sequences are as follows:
Seq1-ManB: GTGATAAATATGGTCGTGTTGAGGATAAATAATTATATGAATATTACCAATGATGTAATTAAAAATAGCGGAATTGCATTTGGTACAAGTGGTGCTCGTGGATTAGTGAAAGATTTTACACCCAACGTGTGTGCTGCATTCACTTATGCTTTTATCGATGTAATGATGAAGGATTTTTCTTTTAAAGAGGTTGCGCTCGCAATAGATAATCGCCCAAGCAGCTATGCTATGGCACAAGCTTGCGCAGCAGCATTGTTGGAATGTAGTATTAAACCTATTTACTACGGTGTAATTCCAACTCCAGCTTTGGCAAATCAAGCGATTGCCGATGGGATTCCTGCAATAATGGTTACTGGAAGTCATATTCCATTTGATAGAAATGGTTTGAAATTCTATCGTCCAGACGGGGAAATTTCAAAAGAAAATGAGAACAGCATTATACATGCTGAAAAAGAGTATCCTGATGTAACTGTATTGCCAGAATTACAATGTTCAAAGCGTGCCGCTGATACTTATATCGAGAGAAACACTTCAATTTTTTCAAATATATTTAAAGGTAAACGTATCGGGATTTATGAACATTCAAGTGCGGGACGGGATCTTTATTCAGAAATATTCAGTAAGCTTGGTGCTGAAGTTGTAAGTATTGGTAGAAGTGATGAGTTTGTGCCTATTGATACTGAAGCAGTATCAAAAGAAGATGAAGAAAAAGCTTTACACTGGTCATCTGAGTATGACCTCGATATGATTTTTTCTACCGATGGTGATGGCGATCGTCCTTTGGTTGCTGACGAAAATGGCGTTTGGTTACGGGGTGATATATTAGGACTATTTTGCTCAAAGGCAATGAATATTGAAGCGGTAGCTGTACCTGTAAGTTGTAATACGGTTATTCAGACTTGCGGGTGGTTTAATCATGTAACGCTGACTAAAATTGGTTCACCATACGTCATTTCAGCGTTTGATTCTCTGAATAATAGTTTTGATAGGGTTGCAGGGTTTGAGGCTAACGGTGGGTATCTTTTAGGTAGCGATGTAAATTATAACAGCGGTATGATTAAAGCGCTTCCAACAAGAGATGCTGTTTTGCCTGCTTTAATGGTACTGGCACTGGCTATAAAAAATAATGTGACTATTTCAAAACTCTTGGCGGAGTTGCCACCACGATTTACCTACTCAAATAGAGTTCAAAATTTTGCAACAAGCAAAAGCAAAAGCAAAAGCATTATTGCGTCAGCTCAAGAAAATCCTCAAGAATTTATCGAAAGAATAGGCTTTGTCGATCTTCATGTACAATCGGTGGATACAATTGACGGGTTAAGATTGACACTAAGTGATGGTTCAATAATCCATTTGCGACCGTCAGGCAACGCACCTGAATTGCGATGCTATGCAGAAGCAGATAACATAATAAAAGCTGAAAAATTAGTGTTAGAAGTTTTGCATAAAGTTACTCTTTTGTAA
Seq2-manC: ATGAGCTCACCTCTTATTCCGGTTATATTAAGTGGTGGTAATGGTACTAGGTTATGGCCACTATCTAGAGAGGAATATCCTAAGCAGTTTTTAAAACTAACCGACTCAATATCAATGCTGCAATCAACAATATCTCGGTTAGACTCATTAAATACTTCCTCTCCAGTTGTAATATGCAATGAATTACACAGATTTATTGTTGCAGAACAACTCAGGCACTTAAATAAATTAGATAATAATATTATTTTAGAACCATCTGGTCGCAATACTGCACCTGCTATTTGTATTGCTGCTTTAATTTTAAAAATGAAGCATCCAAATGAAAATCCACTTATGCTCGTTCTTCCAGCCGATCACTCCGTAAAAAAAGTCAAAACTTTTTGTAATACAATAAAAAGTGCTATTCCCTTCGCTGAAGCTGGTAATTTGGTTTCTTTTGGTATTAAACCTACTCATCCTGAGACGGGGTATGGATATATACAAAAAGGCAAAGTGTTATCTGATTCTGATATATATGAGGTCAGTGAAGTTAGAACTTTTGTTGAAAAGCCTAATCTTAAAACAGCAGAAAGCTTTATAGAAAAAGATGAGTATTATTGGAATAGTGGTATGTATTTGTTCAGTGTTGAACGTTACTTACAAGAGTTATCATTATACCGACCAGACATAGTTAAAGTATGCCAGGAAACTGTTAAAAATATTCATTATGATATGGATTTTATTAGATTGGACGATAAAATATTTCGGAACTGTCCACAGGAGTCTATTGATTATGCTGTAATGGAGAAAACAAAGGATGCTGTAGTTGCTACAATGGATATCGGTTGGAATGATGTAGGAGCATGGTCTTCGCTTTGGGAATTAGGGAAAAAAGACTCCTCTGGTAATGTTATCACGGGAGACATCGTTTGCCACGAGACAGAAAATAGTTATATTTATACTGAGTCTGGATTGGTAGCAACTATTGGTATTCAAGATCTTGTTATTATTCATACTAAAGATTCATTACTGGTTTCCAGACGCGATTCAGTACAAAATGTAAAAAATATTGTTCAGCATCTTGATTTGTCAGGACGTAAAGAACATAAAGAACATAGGGAAGTATTCAAGTCATGGGGACGATGTGACTCCATAGATAGTAGTGAAAAGTACCACTATCAGGTCAAACGAATAACAGTTAATCCAAGTGAAAAATTATCGTTGCAATTACATCATCACCGTGCGGAACATTGGGTTGTTGTAATGGGGATTGCTAAACTTACAGTTGCAGAAGAAATAAAAATTTTAAAAGAGAATGAGTCTGTATATATTCCTGCAGGTATTAAGCATAGTTTGGAAAATATTGGGACAATACCACTTGTGTTAATAGAAGTTTGGACCGGTTCTTATCTTGCTGATGATGATATCCTTCGATTTGAAGATTGA
Seq3-gmd:
ATGTCAAAAGTCGCTCTCATCACCGGTGTAACCGGACAAGACGGTTCTTACCTGGCAGAGTTTCTGCTGGAAAAAGGTTACGAGGTGCATGGTATTAAGCGTCGCGCATCGTCATTCAACACCGAGCGCGTGGATCACATTTATCAGGATCCGCACACCTGCAACCCGAAATTCCATCTGCATTATGGCGACCTGAGTGATACCTCTAACCTGACGCGCATTTTGCGTGAAGTACAGCCGGATGAAGTGTACAACCTGGGCGCAATGAGCCACGTTGCGGTCTCTTTTGAGTCACCAGAATATACCGCTGACGTCGACGCGATGGGTACGCTGCGCCTGCTGGAGGCGATCCGCTTCCTCGGTCTGGAAAAGAAAACTCGTTTCTATCAGGCTTCCACCTCTGAACTGTATGGTCTGGTGCAGGAAATTCCGCAGAAAGAGACCACGCCGTTCTACCCGCGATCTCCGTATGCGGTCGCCAAACTGTACGCCTACTGGATCACCGTTAACTACCGTGAATCCTACGGCATGTACGCCTGTAACGGAATTCTCTTCAACCATGAATCCCCGCGCCGCGGCGAAACCTTCGTTACCCGCAAAATCACCCGCGCAATCGCCAACATCGCCCAGGGGCTGGAGTCGTGCCTGTACCTCGGCAATATGGATTCCCTGCGTGACTGGGGCCACGCCAAAGACTACGTAAAAATGCAGTGGATGATGCTGCAGCAGGAACAGCCGGAAGATTTCGTTATCGCGACCGGCGTTCAGTACTCCGTGCGTCAGTTCGTGGAAATGGCGGCAGCACAGCTGGGCATCAAACTGCGCTTTGAAGGCACGGGCGTTGAAGAGAAGGGCATTGTGGTTTCCGTCACCGGGCATGACGCGCCGGGCGTTAAACCGGGTGATGTGATTATCGCTGTTGACCCGCGTTACTTCCGTCCGGCTGAAGTTGAAACGCTGCTCGGCGACCCGACCAAAGCGCACGAAAAACTGGGCTGGAAACCGGAAATCACCCTCAGAGAGATGGTGTCTGAAATGGTGGCTAATGACCTCGAAGCGGCGAAAAAACACTCTCTGCTGAAATCTCACGGCTACGACGTGGCGATCGCGCTGGAGTCATAA
Seq4-flc:
ATGAGTAAACAACGAGTTTTTATTGCTGGTCATCGCGGGATGGTCGGTTCCGCCATCAGGCGGCAGCTCGAACAGCGCGGTGATGTGGAACTGGTATTACGCACCCGCGACGAGCTGAACCTGCTGGACAGCCGCGCCGTGCATGATTTCTTTGCCAGCGAACGTATTGACCAGGTCTATCTGGCGGCGGCGAAAGTGGGCGGCATTGTTGCCAACAACACCTATCCGGCGGATTTCATCTACCAGAACATGATGATTGAGAGCAACATCATTCACGCCGCGCATCAGAACGACGTGAACAAACTGCTGTTTCTCGGATCGTCCTGCATCTACCCGAAACTGGCAAAACAGCCGATGGCAGAAAGCGAGTTGTTGCAGGGCACGCTGGAGCCGACTAACGAGCCTTATGCTATTGCCAAAATCGCCGGGATCAAACTGTGCGAATCATACAACCGCCAGTACGGACGCGATTACCGCTCAGTCATGCCGACCAACCTGTACGGGCCACACGACAACTTCCACCCGAGTAATTCGCATGTGATCCCAGCATTGCTGCGTCGCTTCCACGAGGCGACGGCACAGAATGCGCCGGACGTGGTGGTATGGGGCAGCGGTACACCGATGCGCGAATTTCTGCACGTCGATGATATGGCGGCGGCGAGCATTCATGTCATGGAGCTGGCGCATGAAGTCTGGCTGGAGAACACCCAGCCGATGTTGTCGCACATTAACGTCGGCACGGGCGTTGACTGCACTATCCGCGAGCTGGCGCAAACCATCGCCAAAGTGGTGGGTTACAAAGGCCGGGTGGTTTTTGATGCCAGCAAACCGGATGGCACGCCGCGCAAACTGCTGGATGTGACGCGCCTGCATCAGCTTGGCTGGTATCACGAAATCTCACTGGAAGCGGGGCTTGCCAGCACTTACCAGTGGTTCCTTGAGAATCAAGACCGCTTTCGGGGGTAA
Seq5-futC:
ATGGCTTTTAAGGTGGTGCAAATTTGCGGGGGGCTTGGGAATCAAATGTTTCAATACGCTTTCGCTAAAAGTTTGCAAAAACACTCTAATACGCCTGTGCTGTTAGATATTACTTCTTTTGATTGGAGCGATAGGAAAATGCAATTAGAGCTTTTCCCTATTGATTTGCCCTATGCGAGTGAAAAAGAAATCGCTATAGCTAAAATGCAACACCTCCCCAAGCTAGTAAGAGACGCGCTCAAATGCATGGGGTTTGATAGGGTGAGCAAAGAAATCGTTTTTGAATACGAGCCTGAATTGTTAAAACCAAGCCGCTTGACTTATTTTTATGGTTACTTTCAAGATCCACGATATTTTGATGCTATATCTCCTTTAATCAAGCAAACCTTCACCCTACCCCCCCCCCCCCCCGAAAATGGAAATAATAAAAAAAAAGAGGAAGAATACCACCGCAAACTTGCTTTGATTTTAGCCGCTAAAAACAGCGTGTTTGTGCATATAAGAAGAGGGGATTATGTGGGGATTGGCTGTCAGCTTGGCATTGATTATCAAAAAAAGGCACTTGAGTATATGGCAAAGCGCGTGCCAAACATGGAGCTTTTTGTGTTTTGCGAAGACTTAACATTCACGCAAAACCTTGATCTGGGCTACCCTTTTATGGACATGACCACTAGGGATAAAGAAGAAGAGGCGTATTGGGACATGCTGCTCATGCAATCTTGTCAGCATGGCATTATCGCTAATAGCACTTATAGCTGGTGGGCGGCTTATTTGATAAACAATCCAGAAAAAATCATTATTGGCCCTAAACACTGGCTTTTTGGGCATGAGAATATCCTTTGTAAGGAATGGGTGAAAATAGAATCCCATTTTGAGGTGAAATCCCAAAAGTATAACGCTTAA
Seq6-scrB:
ATGACAGCACATGACCAGGAGCTTCGTCGCCGGGCTTATGAAGAAGTGGAGAAAAAAGAGCCCATCGCTAACAGCGATCCGCACCGCCAGCATTTTCATATCATGCCGCCGGTTGGGCTGCTGAATGACCCGAATGGCGTGATTTATTGGAAGGGCAGCTATCATGTATTCTTTCAGTGGCAGCCGTTTCAGACGGGGCACGGCGCAAAATTTTGGGGGCATTATACGACACAGGATGTTGTGAATTGGAAGCGGGAAGAGATTGCGCTGGCTCCGAGTGATTGGTTTGATAAAAACGGCTGCTACTCGGGCAGCGCTGTCACGAAAGACGATCGGCTCTATCTTTTTTACACAGGAAATGTCAGGGATCAGGATGGAAATCGGGAAACGTATCAATGCCTTGCTGTTTCTGACGACGGGCTGTCCTTTGAGAAAAAGGGTGTCGTCGCCCGCCTTCCGGAAGGATATACGGCGCATTTTCGCGATCCGAAGGTATGGGAGCATGAAGGCACATGGTATATGGTGATTGGTGCGCAAACAGAGAATTTGAAAGGGCAGGCTGTGTTGTTTGCTTCTGATAACCTGACAGAGTGGAGATTTCTTGGCCCGATAACCGGCGCGGGCTTCAACGGGCTGGACGATTTTGGATACATGTGGGAATGCCCTGATTTGTTTTCCCTTCAAGGATCGGATGTGCTGATTGTTTCGCCTCAAGGGCTTGAGGCTGACGGTTTCCGTTATCAGAACGTATATCAATCAGGTTATTTTGTCGGCCGCCTCGATTATAACAAGCCTGAACTGAAGCATGGTGAATTTACGGAGCTTGATCAAGGTTTTGATTTTTACGCGCCGCAAACACTTGAAGACGATCAGGGAAGGCGGATTTTATTTGCATGGATGGCGGTGCCTGATCAGGATGAAGGGTCCCATCCGACCATTGACTGCCACTGGATTCACTGCATGACGCTGCCGAGACAGCTGACGCTTTCAGGACAGAAGCTGATTCAGCAGCCGCTGCCTGAGCTAAAAGCCATGCGCAGAAATGAGAAAAAAATACACATCAACATGCATGGATCATCTGGTGCGCTTCCAGTGGAAAAACCTGAAAGAACTGAGATTCTACTGGAAGACATTCATACGGAGTCTGGCTTTTCAATCAGTATCCGCGGAACGGCTACGTTTTCCTTCCATAAAGACGAGGGGATTGTTACGCTGGAACGAAAGAGCTTTGACGGAAAAAGAACAGAAGCGAGACATTGCCGCATCAAGGATTTGCATACCGTACACATGTTTCTCGACGCGTCATCTGTGGAAATCTTTATCAATAACGGAGAAGAGGTCTTGAGTGCAAGATATTTTCCTTTCCCGGGAAATCATGAAGTAACAGCCAGTGCGACCGGGAAATCTGAAATGAATGTCGGAATTTGGACACTTATGTAG
Seq7-scrY:
ATGTATAAAAAAACAACTTTGGCAGTGTTAATTGCTTTGCTGACCGGTGCTACAACGGTACATGCGCAAACGGATATTAGCAGTATCGAATCTCGACTGGCGGCGTTGGAACAACGTTTAAAAAATGCGGAATCCCGCGCCCAGGCGGCAGAAGCAAGGGCCAAAACAGCTGAATTACAGGTTCAGAAACTGGCTGAAACACAACAACAAAATCAGCTAACAACTCAAGAAGTAGCACAGAGAACAGTTCAGCTCGAACAGAAATCCGCAGAAAACAGTGGTTTTGAGTTTCATGGCTATGCCCGTTCCGGGTTACTGATGAATGATGCCGCTTCCAGTAGCAAAAGTGGGCCGTATCTGACTCCCGCAGGTGAAACTGGTGGAGCTGTTGGCCGTCTGGGAAATGAAGCCGATACCTATGTCGAGTTAAATGTAGAACATAAACAAACACTGGATAACGGTGCGACCACACGCTTTAAAGCAATGTTGGCTGACGGACAAAGAGATTACAACGACTGGACTGGCGGCTCCAGTAACCTGAATATCCGACAGGCTTTTGCCGAACTGGGCGCATTACCAAGTTTTACCGGAGCATTCAAAGACAGTACTGTCTGGGCTGGTAAACGCTTTGATCGCGACAATTTTGATATTCACTGGTTAGACTCCGATGTCGTATTTTTAGCGGGAACGGGCGGCGGTATCTATGACGTAAAATGGAACGATACATTCCGCAGTAACTTTTCTCTCTACGGACGTAATTTCGGCGATCTTGATGATATCGACAATAACGTTCAGAACTACATCCTCACCATGAATCATTATGCAGGCCCCTTCCAGTTGATGGTTAGCGGATTACGGGCAAAAGATAATGATGATCGAAAAGATGCCAATGGTGATCTCATTCAAACTGATGCTGCAAATACTGGCGTACATGCGTTAGTTGGTCTGCACAATGACACTTTCTATGGCCTGCGTGAAGGGACGGCAAAAACAGCACTGCTATATGGCCATGGCCTGGGTGCGGAAGTCAAAGGGATTGGCTCCGATGGCGCTCTGCTGTCTGAGGCGAATACCTGGCGCTTCGCATCTTACGGCACAACACCTCTGGGAAGCGGTTGGTATGTTGCGCCAGCAATTCTCGCACAAAGCAGTAAAGATCGTTACGTCAAAGGCGATAGCTACGAATGGGTGACCTTCAATACACGTCTGATCAAAGAGGTAACACAGAATTTTGCTCTGGCCTTTGAGGGTAGCTATCAATATATGGATCTGAAGCCAAAGGGGTATCAAAACCACAACGCCGTAAACGGCAGCTTCTATAAACTCACCTTTGCTCCAACTCTAAAAGCTAACGATATCAATAATTTCTTTAGCCGTCCGGAGCTTCGCCTGTTTGCCACCTGGATGGACTGGAGCAGCAAACTTGATGATTTTGCCAGCAATGACGCTTTCGGCAGCAGTGGTTTCAATACTGGCGGAGAGTGGAATTTTGGTGTCCAAATGGAAACCTGGTTTTAA
Seq8-lacY:
ATGTACTATTTAAAAAACACAAACTTTTGGATGTTCGGTTTATTCTTTTTCTTTTACTTTTTTATCATGGGAGCCTACTTCCCGTTTTTCCCGATTTGGCTACATGACATCAACCATATCAGCAAAAGTGATACGGGTATTATTTTTGCCGCTATTTCTCTGTTCTCGCTATTATTCCAACCGCTGTTTGGTCTGCTTTCTGACAAACTCGGGCTGCGCAAATACCTGCTGTGGATTATTACCGGCATGTTAGTGATGTTTGCGCCGTTCTTTATTTTTATCTTCGGGCCACTGTTACAATACAACATTTTAGTAGGATCGATTGTTGGTGGTATTTATCTAGGCTTTTGTTTTAACGCCGGTGCGCCAGCAGTAGAGGCATTTATTGAGAAAGTCAGCCGTCGCAGTAATTTCGAATTTGGTCGCGCGCGGATGTTTGGCTGTGTTGGCTGGGCGCTGTGTGCCTCGATTGTCGGCATCATGTTCACCATCAATAATCAGTTTGTTTTCTGGCTGGGCTCTGGCTGTGCACTCATCCTCGCCGTTTTACTCTTTTTCGCCAAAACGGATGCGCCCTCTTCTGCCACGGTTGCCAATGCGGTAGGTGCCAACCATTCGGCATTTAGCCTTAAGCTGGCACTGGAACTGTTCAGACAGCCAAAACTGTGGTTTTTGTCACTGTATGTTATTGGCGTTTCCTGCACCTACGATGTTTTTGACCAACAGTTTGCTAATTTCTTTACTTCGTTCTTTGCTACCGGTGAACAGGGTACGCGGGTATTTGGCTACGTAACGACAATGGGCGAATTACTTAACGCCTCGATTATGTTCTTTGCGCCACTGATCATTAATCGCATCGGTGGGAAAAACGCCCTGCTGCTGGCTGGCACTATTATGTCTGTACGTATTATTGGCTCATCGTTCGCCACCTCAGCGCTGGAAGTGGTTATTCTGAAAACGCTGCATATGTTTGAAGTACCGTTCCTGCTGGTGGGCTGCTTTAAATATATTACCAGCCAGTTTGAAGTGCGTTTTTCAGCGACGATTTATCTGGTCTGTTTCTGCTTCTTTAAGCAACTGGCGATGATTTTTATGTCTGTACTGGCGGGCAATATGTATGAAAGCATCGGTTTCCAGGGCGCTTATCTGGTGCTGGGTCTGGTGGCGCTGGGCTTCACCTTAATTTCCGTGTTCACGCTTAGCGGCCCCGGCCCGCTTTCCCTGCTGCGTCGTCAGGTGAATGAAGTCGCTTAA
Seq10-PssA:
GTAAGAAACAGCACGATAAACGTTCAGATATCAAAGAGCGCGAATGGCAGGTGGATAAAGCACGTATCATGAAAAACGCCCACCGTTAAACCTGCACTCCAATTATTGACCAGTTCCTCACCGCGCCTCCCTCTCCGGCGGCGCGAATGAACATCTTATTGGCTATCACATCCGACACAAATGTTGCCATCCCATTGCTTAATCGAATAAAAATCAGGCTACATGGGTGCTAAATCTTTAACGATAACGCCATTGAGGCTGGTCATGGCGCTCATAAATCTGGTATACTTACCTTTACACATTG。
Claims (4)
1. 2' -fucosyllactose high-yield strain(s) ((Escherichia coli) The method is characterized in that: the preservation number is CGMCC No. 19557.
2. A2' -fucosyllactose high-producing strain(s) according to claim 1 (a)Escherichia coli) The preparation method is characterized in that: comprises the following steps:
(1) construction ofE.coliBL21(DE3)-1:
To be provided withEscherichia coliMG1655 genome is used as template, designing primer: an upstream primer:manB-F: CCGGAATTCATGATAAATATGGTCGTGTTGAGGA, downstream primer:manB-R: CGCGGATCCTTACAAAAGAGTAACTTTATGCAAA, respectively; PCR amplification phosphomannose mutase expression genemanBA sequence; the PCR product was reacted with pCDF-Duet plasmidEcoRI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product ismanBConnecting the gene fragment and the pCDF-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:manC-F: CCCAAGCTTATGAGCTCACCTCTTATTCCGGTTA, downstream primer:manC-R: AAATATGCGGCCGCTCAATCTTCAAATCGAAGGATATCA, respectively; PCR amplification of mannose-1-phosphate guanylyltransferase expression GeneDue to the fact thatmanCA sequence; the PCR product was mixed with pCDF-Duet-manBPlasmid carrying outHindIII/NotI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productmanCGene fragment and pCDF-Duet-manBCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB-manC;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:gmd-F: GGGAATTCCATATGTCAAAAGTCGCTCTCATCACCG, and the downstream primer:gmd-R: CGGGGTACCATGTCAAAAGTCGCTCTCATCACCG, respectively; PCR amplification of GDP-mannose-4, 6-dehydratase expression genegmdA sequence; the PCR product was mixed with pCDF-Duet-manB-manCPlasmid carrying outNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productgmdGene fragment and pCDF-Duet-manB-manCCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a streptomycin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain successfully constructed plasmid pCDF-Duet-manB-manC-gmd;
To be provided withE. coliMG1655 genome is used as template, and upstream primer is designed:flc-F: CCGGAATTCATGAGTAAACAACGAGTTTTTATTG, downstream primer:flcCGCGGATCCTTACCCCCGAAAGCGGTCTTGATTC, PCR amplification of GDP-L-fucose synthase expression GeneflcA sequence; the PCR product was reacted with pACYC-Duet plasmidEcoRI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product isflcConnecting the gene fragment and the pACYC-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a chloramphenicol resistant plate, plasmid extraction and enzyme digestion or PCR verification are carried out, and the successfully constructed plasmid pACYC-Duet-flc;
Based onHelicobacter pyloriProvided in the genomeα -1, 2-fucosyltransferase, designing an upstream primer:futC-F: GGGAATTCCATATGGCTTTTAAGGTGGTGCAAATTT, downstream primer:futCCGCGGATCCTTAAGCGTTATACTTTTGGGATTTC, PCR amplification α -1, 2-fucosyltransferase gene, and the PCR product and pACYC-Duet plasmidNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productfutCGene fragment and pACYC-Duet-flcCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 is competent, transformants are screened and cultured by a chloramphenicol resistant plate, plasmid extraction and enzyme digestion or PCR verification are carried out, and the successfully constructed plasmid pACYC-Duet-flc-futC(ii) a The above plasmid pCDF-Duet-manB-manC-gmd、pACYC-Duet-flc-futCConstruction of transformed E.coli B L21 (DE3)E.coliBL21(DE3)-1;
(2) Constructing to obtain recombinant strainE.coliBL21(DE3)-3:
Using Bacillus subtilis (B), (B)Bacillus subtilis) 168 genome is used as a template, and an upstream primer is designed:scrB-F: CATGCCATGGATGACAGCACATGACCAGGAGCTTC, downstream primer:scrB-R: CGCGGATCCCTACATAAGTGTCCAAATTCCGACA, respectively; PCR amplification of scrB expression gene of one of sucrose transportersscrBA sequence; the PCR product was reacted with pET-Duet plasmidNcoI/BamHI double enzyme digestion, enzyme digestion product is recovered and purified by glue, and the obtained product isscrBConnecting the gene fragment and pET-Duet plasmid enzyme digestion fragment by using DNA ligase overnight; the ligation product is converted by heat shockE. coliJM109 competes, transformants are screened and cultured by an ampicillin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain the successfully constructed plasmid pET-Duet-scrB;
To be provided withE. coliThe K-12 genome is used as a template, and an upstream primer is designed:scrY-F: GGGAATTCCATATGATGTATAAAAAAACAACTTTGGCAG, downstream primer:scrY-R: CGGGGTACCTTAAAACCAGGTTTCCATTTGGACA, respectively; PCR amplification of scrY expression gene of one of sucrose transportersscrYA sequence;
the PCR product was reacted with pET-Duet plasmidNdeI/KpnI double enzyme digestion, recovering and purifying the enzyme digestion product by glue, and then carrying out the purification on the obtained productscrYGene fragment and pET-Duet-scrBCarrying out overnight connection on the plasmid digestion fragments by using DNA ligase; the ligation product is converted by heat shockE. coliJM109 competes, transformants are screened and cultured by an ampicillin resistance plate, and plasmid extraction and enzyme digestion or PCR verification are carried out to obtain the successfully constructed plasmid pET-Duet-scrB-scrY(ii) a The plasmid pET-Duet-scrB - scrYTransformation of the plasmid intoE. coliB L21 (DE3) -1, recombinant strains were obtainedE.coliBL21(DE3)-2;
To be provided withE. coliB L21 (DE3) genome as template, designing sgRNA and homology arm primer for gene knockout, PCR amplifying lacZ gene upstream and downstream homology arms, obtaining pure knockout gene segment after recovery of glue, and graftingE. coliB L21 (DE3)/pKD46 was cultured at 30 ℃ and OD600When 0.1 was reached, L-arabinose was added at a final concentration of 0.2% to induce expression of pKD 46-lambda-red system when OD was reached600When the gene reaches 0.3-0.4, preparing competence, adding a knockout gene segment into the competence, and after electrotransformation, knocking out the knockout gene segmentlacZGene to obtain recombinant bacteriumE. coliBL21(DE3)-2/△lacZ;
The recombinant strain is prepared byE.coliBL21(DE3)-2/△lacZRespectively designing for starting strainslacY-F: GGGAATTCCATATGATGTACTATTTAAAAAACACAAACT, downstream primer:lacY-R: CGCGGATCCTTAAGCGACTTCATTCACCTGACGA, amplificationE. colilacY-expressing Gene in K-12lacYRespectively fusing the gene with a strong promoter PssrA in escherichia coli through fusion PCR to construct a high-efficiency expression reading coding frame of lacY; then, the expression cassette is integrated into the recombinant strain by using a homologous integration system in Escherichia coli, and the recombinant strain is constructedE.coliB L21 (DE3) -3, 2' -fucosyllactose high producing strainEscherichia coli。
3. The application of the 2'-fucosyllactose high-producing strain of claim 1 in improving the yield of 2' -F L is characterized in that a recombinant strain is usedE.coliB L21 (DE3) -3 inoculation into seed MediumCulturing at 37 deg.C overnight; determining OD at 30 ℃6000.8 hours, 0.5 mM IPTG was added, and the fermentation time was 96 hours, under which conditions the concentrations of sucrose and fructose in the fermentation medium were 30 g/L and 20 g/L, respectively.
4. The application of the 2'-fucosyllactose high-producing strain of claim 1 in improving the yield of 2' -F L is characterized in that a recombinant strain is usedE.coliA single colony of B L21 (DE3) -3 strain is cultured in a seed solution with a liquid loading of 100 m L at 30 ℃ and 180r/min by a rotary shaking table to OD600The method is characterized by taking the seed liquid with the concentration of 10.0 percent approximately as the seed liquid, inoculating 60 m L of the seed liquid into a fermentation culture medium with the working volume of 3L with the inoculation amount of 2.0 percent, fermenting at the fermentation temperature of 33 ℃ in a fermentation tank, stirring at the rotating speed of 600 r/min, ventilating at the volume of 1vvm and pH of 6.8, adding IPTG with the concentration of 50 mg/m L in 1-2 m L during the logarithmic growth phase, feeding cane sugar after the logarithmic phase is ended until the concentration is 22 g/L, feeding at the initial 6h at the feeding rate of 9 m L/h, then feeding at the rate of 9 m L/h for 115 h, and feeding the fermentation liquid 2' -F L with the concentration of 100 g/L after the fermentation is ended.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010379802.3A CN111471637A (en) | 2020-05-08 | 2020-05-08 | 2' -fucosyllactose high-yield strain and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010379802.3A CN111471637A (en) | 2020-05-08 | 2020-05-08 | 2' -fucosyllactose high-yield strain and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111471637A true CN111471637A (en) | 2020-07-31 |
Family
ID=71762118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010379802.3A Pending CN111471637A (en) | 2020-05-08 | 2020-05-08 | 2' -fucosyllactose high-yield strain and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111471637A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112011583A (en) * | 2020-09-10 | 2020-12-01 | 苏州一兮生物科技有限公司 | Method for synthesizing 2' -FL in escherichia coli by utilizing microbial quorum sensing and application |
CN112342176A (en) * | 2020-10-15 | 2021-02-09 | 江南大学 | Genetic engineering bacterium for producing 2' -fucosyllactose and application thereof |
CN112625987A (en) * | 2020-12-21 | 2021-04-09 | 南通励成生物工程有限公司 | Method for simultaneously producing 2' -fucosyllactose and D-psicose |
CN113462629A (en) * | 2021-07-20 | 2021-10-01 | 南通励成生物工程有限公司 | Method for increasing yield of 2' -fucosyllactose synthesized by escherichia coli engineering bacteria |
CN116218892A (en) * | 2023-02-13 | 2023-06-06 | 天津科技大学 | Construction method and application of CLM24 (DE 3) strain |
CN116479070A (en) * | 2023-06-20 | 2023-07-25 | 山东合成远景生物科技有限公司 | Fermentation production method for improving yield of fucosyllactose of escherichia coli |
WO2023216685A1 (en) * | 2022-05-10 | 2023-11-16 | 南通励成生物工程有限公司 | Strain for synthesizing 2'-fucosyllactose by taking glucose as carbon source, construction method therefor, and use thereof |
CN117597451A (en) * | 2021-05-17 | 2024-02-23 | 帝斯曼知识产权资产管理有限公司 | Enhanced HMO formation by modifying intracellular lactose import |
CN118256536A (en) * | 2024-03-13 | 2024-06-28 | 合曜生物科技(南京)有限公司 | Recombinant escherichia coli for high yield of 2' -fucosyllactose as well as construction method and application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1433467A (en) * | 1999-12-21 | 2003-07-30 | 协和发酵工业株式会社 | Modified alpha-1, 2-fucosyl transferase gene and process for producing alpha-1, 2-fucosyl transferase and fucose-containing sugar chain |
WO2016153300A1 (en) * | 2015-03-24 | 2016-09-29 | 서울대학교 산학협력단 | 2-fucosyllactose producing mutant microorganisms and method for producing 2-fucosyllactose using same |
CN106190937A (en) * | 2016-07-18 | 2016-12-07 | 南开大学 | A kind of method building recombination bacillus coli biosynthesis 2 ' rock algae lactose |
US20170175154A1 (en) * | 2014-06-27 | 2017-06-22 | Glycom A/S | Oligosaccharide production |
CN107849577A (en) * | 2016-04-25 | 2018-03-27 | 首尔大学校产学协力团 | Utilize the production method of the 2 ' fucosyllactoses of corynebacterium glutamicum |
CN109402158A (en) * | 2018-09-14 | 2019-03-01 | 江苏大学 | A kind of recombinant expression plasmid carrier, metabolic engineering bacteria and production method producing fucosyllactose |
CN109790559A (en) * | 2016-10-29 | 2019-05-21 | 詹尼温生物技术有限责任公司 | The method for generating fucosylated oligosaccharide of improvement |
CN110637091A (en) * | 2018-04-04 | 2019-12-31 | 高级蛋白质技术公司 | Method for producing 2' -fucosyllactose using fucosyltransferase derived from Agrobacterium choreoides |
-
2020
- 2020-05-08 CN CN202010379802.3A patent/CN111471637A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1433467A (en) * | 1999-12-21 | 2003-07-30 | 协和发酵工业株式会社 | Modified alpha-1, 2-fucosyl transferase gene and process for producing alpha-1, 2-fucosyl transferase and fucose-containing sugar chain |
US20170175154A1 (en) * | 2014-06-27 | 2017-06-22 | Glycom A/S | Oligosaccharide production |
WO2016153300A1 (en) * | 2015-03-24 | 2016-09-29 | 서울대학교 산학협력단 | 2-fucosyllactose producing mutant microorganisms and method for producing 2-fucosyllactose using same |
CN107849577A (en) * | 2016-04-25 | 2018-03-27 | 首尔大学校产学协力团 | Utilize the production method of the 2 ' fucosyllactoses of corynebacterium glutamicum |
CN106190937A (en) * | 2016-07-18 | 2016-12-07 | 南开大学 | A kind of method building recombination bacillus coli biosynthesis 2 ' rock algae lactose |
CN109790559A (en) * | 2016-10-29 | 2019-05-21 | 詹尼温生物技术有限责任公司 | The method for generating fucosylated oligosaccharide of improvement |
CN110637091A (en) * | 2018-04-04 | 2019-12-31 | 高级蛋白质技术公司 | Method for producing 2' -fucosyllactose using fucosyltransferase derived from Agrobacterium choreoides |
CN109402158A (en) * | 2018-09-14 | 2019-03-01 | 江苏大学 | A kind of recombinant expression plasmid carrier, metabolic engineering bacteria and production method producing fucosyllactose |
Non-Patent Citations (1)
Title |
---|
FOOD STANDARDS: "Safety, technical and health effects assessment – Application A1155 2’-FL and LNnT in infant formula and other products", 《FOOD STANDARDS 》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112011583A (en) * | 2020-09-10 | 2020-12-01 | 苏州一兮生物科技有限公司 | Method for synthesizing 2' -FL in escherichia coli by utilizing microbial quorum sensing and application |
CN112342176A (en) * | 2020-10-15 | 2021-02-09 | 江南大学 | Genetic engineering bacterium for producing 2' -fucosyllactose and application thereof |
CN112625987A (en) * | 2020-12-21 | 2021-04-09 | 南通励成生物工程有限公司 | Method for simultaneously producing 2' -fucosyllactose and D-psicose |
CN112625987B (en) * | 2020-12-21 | 2023-01-06 | 南通励成生物工程有限公司 | Method for simultaneously producing 2' -fucosyllactose and D-psicose |
CN117597451A (en) * | 2021-05-17 | 2024-02-23 | 帝斯曼知识产权资产管理有限公司 | Enhanced HMO formation by modifying intracellular lactose import |
CN113462629A (en) * | 2021-07-20 | 2021-10-01 | 南通励成生物工程有限公司 | Method for increasing yield of 2' -fucosyllactose synthesized by escherichia coli engineering bacteria |
CN113462629B (en) * | 2021-07-20 | 2023-01-10 | 南通励成生物工程有限公司 | Method for increasing yield of 2' -fucosyllactose synthesized by escherichia coli engineering bacteria |
WO2023216685A1 (en) * | 2022-05-10 | 2023-11-16 | 南通励成生物工程有限公司 | Strain for synthesizing 2'-fucosyllactose by taking glucose as carbon source, construction method therefor, and use thereof |
CN116218892A (en) * | 2023-02-13 | 2023-06-06 | 天津科技大学 | Construction method and application of CLM24 (DE 3) strain |
CN116479070A (en) * | 2023-06-20 | 2023-07-25 | 山东合成远景生物科技有限公司 | Fermentation production method for improving yield of fucosyllactose of escherichia coli |
CN116479070B (en) * | 2023-06-20 | 2023-08-29 | 山东合成远景生物科技有限公司 | Fermentation production method for improving yield of fucosyllactose of escherichia coli |
CN118256536A (en) * | 2024-03-13 | 2024-06-28 | 合曜生物科技(南京)有限公司 | Recombinant escherichia coli for high yield of 2' -fucosyllactose as well as construction method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111471637A (en) | 2' -fucosyllactose high-yield strain and preparation method and application thereof | |
CN106190937B9 (en) | Method for biosynthesizing 2' -fucosyllactose by constructing recombinant escherichia coli | |
CN109402158B (en) | Recombinant expression plasmid vector for producing fucosyllactose, metabolic engineering bacteria and production method | |
CN107267575B (en) | Method for producing N-acetyl-D-glucosamine and/or D-glucosamine salt by microbial fermentation | |
CN111518782B (en) | Glycosyltransferase UGTZJ1 mutant and application thereof | |
CN114774343B (en) | Coli engineering strain for producing 2' -fucosyllactose and application thereof | |
BR112015029933B1 (en) | TAGATOSE PRODUCTION METHOD | |
CN114874964B (en) | Construction method and application of recombinant escherichia coli for high yield of 2' -fucosyllactose | |
CN106754595A (en) | Recombinant bacterium and application thereof in catalyzing rebaudioside A to generate rebaudioside D | |
CN109890973B (en) | Method for preparing rebaudioside N by enzyme method | |
CN109486834B (en) | Recombinant lactococcus lactis for high yield of nisin and construction method thereof | |
CN116286562B (en) | Genetically engineered bacterium and preparation method and application thereof | |
CN113005132B (en) | D-psicose-3-epimerase gene and application method thereof | |
CN113801240B (en) | D-psicose-3-epimerase activity aggregate and preparation method and application thereof | |
CN115287273A (en) | 1, 2-fucosyltransferase and fusion protein and encoding gene thereof | |
TW202317759A (en) | Novel uridine diphosphate glycosyltransferase and use thereof | |
WO2019100676A1 (en) | Preparation method for enzyme-modified stevioside, enzyme for said preparation method, and application thereof | |
WO2019161634A1 (en) | Preparation method for rebaudioside a, enzyme for rebaudioside a preparation, and application | |
CN111455003A (en) | Method for preparing D-psicose from microalgae | |
CN114934062B (en) | Engineering bacterium for efficiently expressing D-psicose 3-epimerase and application | |
CN116426452A (en) | Recombinant escherichia coli strain for synthesizing 2' -fucosyllactose and application thereof | |
CN110846305B (en) | Method for preparing rebaudioside M by catalyzing rebaudioside A with immobilized glycosyltransferase | |
CN109234340B (en) | Method for catalytically synthesizing rebaudioside M by recombinant yeast | |
CN116254279B (en) | Method for catalyzing xylitol to biosynthesize L-xylose by using double-enzyme cascade recombinant escherichia coli | |
CN114015735B (en) | Method for synthesizing aspergillus niger disaccharide by cascading and catalyzing sucrose phosphorylase and glucose isomerase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200731 |
|
RJ01 | Rejection of invention patent application after publication |